Affilogic is a private biotech company specialised in discovering and developing Nanofitins® through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector.

These affinity proteins are potent antibody-mimetics, exhibiting a high affinity and specificity for capture, targeting and interacting with biomolecules. Each Nanofitin® is 20 times smaller than an antibody (7 kDa) and demonstrates hyper stability. Nanofitins are easily combined with each other, antibodies and other biomolecules by simple, rapid and proven methods to design an ideal targeted molecule.

Affilogic has designed Nanofitins® against 60+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (virus-like particles, bacteria, whole cells).

Meet us

BIO Digital 2020

BIO Digital 2020

Virtually meet us at BIO Digital
June 8-12, 2020

Visit the event website

BIO Europe Spring 2020

BIO Europe Spring 2020

Virtually meet us at BIO Europe Spring 2020
@ Paris, France
March 23-25, 2020

Visit the event website

Competitive Advantages

Nanofitins® Biotherapeutics

Partnering Strategy